Ardelyx offers 28% revenue growth and a forward P/E of 11.0x with roughly 21-to-1 favorable risk/reward and 150% upside to analyst targets, yet business quality sitting just below the minimum floor constrains the position recommendation to avoid until quality metrics recover.
Thesis pillars
- Quality Below Minimum Floor↓Deteriorating
- Compelling Valuation Outsized Asymmetry→Stable
- Strong Revenue Growth Trajectory→Stable
- +1 more pillar — see the Why tab for full reasoning
Ardelyx, Inc. (ARDX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.04: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10. Specifically: High short interest: 11%; Elevated put/call ratio: 3.18; Below-average business quality.
Ardelyx is a commercial-stage biopharmaceutical company marketing two FDA-approved tenapanor-based therapies: IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adult chronic kidney disease dialysis patients. The company says it... Read more
Sell if holding. Engine safety override at $5.04: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10. Specifically: High short interest: 11%; Elevated put/call ratio: 3.18; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.3/10, moderate confidence.
Passes 4/9 gates (clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Ardelyx, Inc.
About Ardelyx, Inc.
Ardelyx markets two FDA-approved tenapanor therapies, IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adult dialysis patients, and says it is substantially dependent on IBSRELA's continued commercialization. As of December 31, 2025, the company held $264.7 million in cash, cash equivalents, and short-term investments against a $946.9 million accumulated deficit, funded partly through a $300.0 million SLR loan facility with $200.0 million drawn.
Ardelyx earns revenue from direct U.S. sales of IBSRELA and XPHOZAH plus upfront payments, development and sales milestones, and royalties from ex-U.S. licensees Knight (Canada), Kyowa Kirin (Japan, marketed as PHOZEVEL), and Fosun Pharma (China), for which Ardelyx also supplies drug substance or finished product under separate supply agreements. Both products rely on third-party contract manufacturers for API and finished dosage forms rather than in-house production. IBSRELA competes against branded secretagogues Linzess and Trulance plus generic lubiprostone in a roughly 13-million-patient IBS-C market, while XPHOZAH competes against six generic phosphate binders and faces a structural headwind: the January 1, 2025 shift of XPHOZAH into the ESRD Prospective Payment System eliminated its separate Medicare Part D coverage, a change Ardelyx says had a negative and material impact on 2025 XPHOZAH revenue even as patient counts grew. The company is also advancing a Phase 3 trial of tenapanor in chronic idiopathic constipation and an early-stage next-generation NHE3 inhibitor, RDX10531.
Show full overview
Ardelyx's core intellectual property protecting tenapanor combines a composition-of-matter patent (U.S. 8,541,448) extended under the Hatch-Waxman Act to August 1, 2033, with method-of-use patents covering phosphorus control expiring around April 2034 and a newly issued formulation patent (U.S. 12,539,299, issued January 22, 2026) covering the commercial IBSRELA and XPHOZAH formulations that runs until November 26, 2042. That formulation patent could give Ardelyx a decade of additional exclusivity beyond the composition patent's 2033 expiration, but its value depends on whether generic challengers can design around the specific formulation claims rather than the underlying tenapanor molecule, a test that has not yet been litigated.
See also: Healthcare · Biotechnology
From Ardelyx, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-25Recent Developments — Ardelyx, Inc.
Latest news
- NEWS Ladenburg Thalmann Assumes Ardelyx at Buy, Announces Price Target of $16 — benzinga Jun 16, 2026 positive
- NEWS Ardelyx Presents Data Analysis Evaluating Long-Term Impact Of XPHOZAH On Serum Electrolytes And Selected Nutrition Bioma — benzinga May 7, 2026 positive
- NEWS Ardelyx Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $94.473M Beat $92.655M Estimate — benzinga Apr 30, 2026 positive
- NEWS Earnings Scheduled For April 30, 2026 — benzinga Apr 30, 2026 neutral
Generated 2026-07-25T17:22:05Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductIBSRELA10-K Item 1A: 'We are substantially dependent on the successful commercialization of IBSRELA, and there is no guarantee that we will maintain sufficient market acceptance for IBSRELA'
Material Events(8-K, last 90d)
- 2026-06-17Item 5.02LOWBoard approved a second amendment to the 2014 Equity Incentive Award Plan on April 16, 2026, subsequently ratified by stockholders at the June 16, 2026 annual meeting; routine equity plan amendment.SEC filing →
- 2026-06-17Item 5.07LOWAt the June 16, 2026 annual meeting, stockholders voted on matters including the Equity Plan Amendment; 247,029,387 shares were entitled to vote as of the April 22, 2026 record date.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.04: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10. Specifically: High short interest: 11%; Elevated put/call ratio: 3.18; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $4.78. Score 6.3/10, moderate confidence.
Take-profit target: $6.14 (+22.1% upside). Prior stop was $4.78. Stop-loss: $4.78.
Concentration risk — Product: IBSRELA; DATA_ISSUE: analyst_target_implausible (raw $16.30 vs price $5.03 — ratio 3.2×). Rejected, falling back to technical TP.; Quality below floor (3.9 < 4.0).
Ardelyx, Inc. trades at a P/E of N/A (forward 9.8). TrendMatrix value score: 9.1/10. Verdict: Sell.
18 analysts cover ARDX with a consensus score of 4.5/5. Average price target: $16.
What does Ardelyx, Inc. do?Ardelyx is a commercial-stage biopharmaceutical company marketing two FDA-approved tenapanor-based therapies: IBSRELA...
Ardelyx is a commercial-stage biopharmaceutical company marketing two FDA-approved tenapanor-based therapies: IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adult chronic kidney disease dialysis patients. The company says it is substantially dependent on IBSRELA's continued commercialization, held a $946.9 million accumulated deficit as of December 31, 2025, and licenses tenapanor to partners including Knight (Canada), Kyowa Kirin (Japan), and Fosun Pharma (China) for royalties and product-supply revenue.